| Identification | More | [Name]
Sodium cinnamate | [CAS]
538-42-1 | [Synonyms]
3-BENZENEPROPENOIC ACID SODIUM SALT
3-PHENYLACRYLIC ACID SODIUM SALT
3-PHENYLPROPENOIC ACID SODIUM SALT
CINNAMIC ACID SODIUM SALT
CINNAMYLIC ACID SODIUM SALT
SODIUM CINNAMATE
2-Propenoicacid,3-phenyl-,sodiumsalt
3-phenyl-2-propenoicacisodiumsalt
fortificar
sodium3-phenyl-2-propenoate
Cinnamate sodium
Benzeneacrylic acid sodium salt
trans-Cinnamic acid sodium salt | [EINECS(EC#)]
208-691-2 | [Molecular Formula]
C9H7NaO2 | [MDL Number]
MFCD00064994 | [Molecular Weight]
170.14 | [MOL File]
538-42-1.mol |
| Chemical Properties | Back Directory | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Methanol (Slightly), Water (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Cosmetics Ingredients Functions]
ANTIMICROBIAL
PERFUMING | [InChI]
InChI=1S/C9H8O2.Na.H/c10-9(11)7-6-8-4-2-1-3-5-8;;/h1-7H,(H,10,11);; | [InChIKey]
QOTHILGGRBOKOP-UHFFFAOYSA-N | [SMILES]
C(C1C=CC=CC=1)=CC(=O)O.[NaH] | [CAS DataBase Reference]
538-42-1(CAS DataBase Reference) | [EPA Substance Registry System]
538-42-1(EPA Substance) |
| Hazard Information | Back Directory | [Chemical Properties]
Sodium cinnamate is a white to light yellow solid at room temperature.It is used in the manufacture of cinnamyl chloride and anticoagulant.Important intermediate of ozagrel, benzyl cinnamate, benzyl chloride,cinnamamide. | [Uses]
Sodium cinnamate can be used to manufacture cinnamic acid, cinnamyl chloride, cinnamamide. At the same time, it is also suitable for improving the cooling system and automobile resistance pad of various engine mechanical equipment, which is beneficial to the long-distance use of automobiles. | [Synthesis]
The commonly used production method of sodium cinnamate is to react cinnamic acid with sodium carbonate aqueous solution, then concentrate and dry it. | [in vivo]
Cinnamic acid sodium (100 mg/kg; gavage) activates PPARα to protect the loss of dopaminergic neurons, restore striatal fibers and neurotransmitters, and improve the behavioral functions in MPTP-intoxicated mice[1]. | Animal Model: | 6-8 weeks, C57BL/6 mice (18 mg/kg MPTP-HCl, i.p.; at 2-h intervals for 4 times)[1] | | Dosage: | 100 mg/kg | | Administration: | Gavage; starting from 3 h after the last injection of MPTP | | Result: | Protected nigral TH levels, protected striatal innervation and neurotransmitters, restored locomotor deficit, increased the activation of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in primary mouse astrocytes, protected striatal TH via PPARα. |
|
|
|